Neurogene Inc. (NGNE) Key Statistics & Metrics

Neurogene Inc. (NGNE) has an ST Score of 47.8 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Wall Street's consensus rating on NGNE is Buy based on 7 analyst ratings. Our own ST Score grades it C+ (47.8/100). This is data, not investment advice — always do your own research.

Neurogene Inc. (NGNE) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Neurogene Inc. (NGNE) earns a growth grade of F, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Neurogene Inc. (NGNE) earns a profitability grade of C+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Neurogene Inc. (NGNE) earns a financial strength grade of B+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Neurogene Inc. (NGNE) is $72.00 from 7 analysts, which is +1.2% versus the recent price of $32.09.

Neurogene Inc. (NGNE) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.